Durable Efficacy of Enfuvirtide Over 48 Weeks in Heavily Treatment-Experienced HIV-1-Infected Patients in the T-20 Versus Optimized Background Regimen Only 1 and 2 Clinical TrialsMark Nelson, Miklos Salgo, Christine Katlama et al.|JAIDS Journal of Acquired Immune Deficiency Syndromes|2005Cited by 151
Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant RecipientsSunwen Chou, Martha Fournier, Camille N. Kotton et al.|The Journal of Infectious Diseases|2023Cited by 77